MedPath

Caffeine, CYPA12 and Resistance Training

Not Applicable
Recruiting
Conditions
CYP1A2 Polymorphism
Caffeine and Resistance Training
Interventions
Dietary Supplement: Caffeine and Resistance training
Dietary Supplement: Placebo and Resistance training
Registration Number
NCT06610123
Lead Sponsor
Alberto Pérez-López
Brief Summary

Introduction: Several studies have evaluated and confirmed the ergogenic effect of acute caffeine intake on sports performance, specifically on strength and power performance. However, it remains to be elucidated how CYP1A2 polymorphism influences the prolonged effects of caffeine on this type of exercise.

Objectives: The present study aims to analyze the prolonged effects of caffeine intake on neuromuscular adaptations to resistance training according to CYP1A2 polymorphism in men and women.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
48
Inclusion Criteria
  • Age between ≥ 18 and ≤ 35 years.
  • Body mass index (BMI) lowe than 25 kg/m².
  • Physically active subjects (≥ 150 min/week of moderate exercise).
  • Healthy men and women without neurological, cardiometabolic, immunological, or physical conditions that prevent them from performing physical exercise.
  • Participants capable of performing the tests.
Exclusion Criteria
  • History of neuromuscular, cardiac, or diseases that could affect liver or muscle metabolism.
  • Use of drugs or other stimulants that interfere with caffeine intake and intestinal absorption during the tests and study.
  • Body mass index (BMI) ≥ 25 kg/m².
  • Having undergone prolonged periods of forced physical inactivity during the 6 months prior to the study.
  • Performing strenuous exercise within 48 hours prior to the tests.
  • Failing to replicate the same food intake on the two experimental days.
  • Consuming caffeine after 6 PM on the day prior to training or testing.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Genotype AA - Male - CaffeineCaffeine and Resistance training-
Genotype AC or CC - Male - CaffeineCaffeine and Resistance training-
Genotype AA - Male - PlaceboPlacebo and Resistance training-
Genotype AC or CC - Male - PlaceboPlacebo and Resistance training-
Genotype AA - Female - CaffeineCaffeine and Resistance training-
Genotype AC or CC - Female - CaffeineCaffeine and Resistance training-
Genotype AA - Female - PlaceboPlacebo and Resistance training-
Genotype AC or CC - Female - PlaceboPlacebo and Resistance training-
Primary Outcome Measures
NameTimeMethod
Mean velocity at different %1RMThrough study completion, an average of 12 weeks

Measuring bar mean velocity desplacement during bench press and back squat exercises.

Peak velocity at different %1RMThrough study completion, an average of 12 weeks

Measuring bar peak velocity and time to reach peak velocity of bar desplacement during bench press and back squat exercises.

Mean power output at different %1RMThrough study completion, an average of 12 weeks

Measuring during bench press and back squat exercises.

Peak power output and time to reach peak power output at different %1RMThrough study completion, an average of 12 weeks

Measuring during bench press and back squat exercises.

Number of repetitions performed at 65%1RM until task failureThrough study completion, an average of 12 weeks

In bench press and back squat exercises

Bar velocity deplacement performed in 1 set at 65%1RM until task failureThrough study completion, an average of 12 weeks

In bench press and back squat exercises

Power output generated in 1 set at 65%1RM until task failureThrough study completion, an average of 12 weeks

In bench press and back squat exercise

Resting Metabolic Rate (RMR)Through study completion, an average of 12 weeks

Kcal at rest using a metabolic chart.

Maximal Fat Oxidation Rate (MFO)Through study completion, an average of 12 weeks

g/min (MFO) using a metabolic chart.

Secondary Outcome Measures
NameTimeMethod
Fat-free massThrough study completion, an average of 4 weeks

Using electrical bioimpedance and untrasound in the quadriceps muscle

Fat massThrough study completion, an average of 12 weeks

Using electrical bioimpedance (kg and % of body mass)

Physical activity (METs-min/wk)Through study completion, an average of 12 weeks

Using IPAQ

Dietary (g/kg of macronutrients)Through study completion, an average of 12 weeks

Using a 24-total recall

Mood stateThrough study completion, an average of 12 weeks

Participants graded a set of 29 items related to the mood on a Likert scale from 0 (not at all) to 4 (extremely) in reply to the question;How do you feel at this moment?; to assess six scales: tension, depression, anger, vigor, fatigue and confusion.

Adverse effectsThrough study completion, an average of 12 weeks

Adverse effects. perception of power, endurance, energy and exertion, as well as heart, muscular and gastrointestinal discomfort.

Trial Locations

Locations (1)

Facultad de Medicina y Ciencias de la Salud. Universidad de Alcalá

🇪🇸

Alcalá de Henares, Madrid, Spain

© Copyright 2025. All Rights Reserved by MedPath